Next Article in Journal
Recombinant Bacillus caldovelox Arginase Mutant (BCA-M) Induces Apoptosis, Autophagy, Cell Cycle Arrest and Growth Inhibition in Human Cervical Cancer Cells
Next Article in Special Issue
B Cell Activating Factor (BAFF) Is Required for the Development of Intra-Renal Tertiary Lymphoid Organs in Experimental Kidney Transplantation in Rats
Previous Article in Journal
Offensive Behavior, Striatal Glutamate Metabolites, and Limbic–Hypothalamic–Pituitary–Adrenal Responses to Stress in Chronic Anxiety
Previous Article in Special Issue
Protective Effects of Simvastatin on Endotoxin-Induced Acute Kidney Injury through Activation of Tubular Epithelial Cells’ Survival and Hindering Cytochrome C-Mediated Apoptosis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia

1
Division of Nephrology, Kyungpook National University Hospital, Daegu 41944, Korea
2
Cell and Matrix Research Institute, Kyungpook National University, Daegu 41944, Korea
3
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(20), 7444; https://doi.org/10.3390/ijms21207444
Submission received: 28 August 2020 / Revised: 28 September 2020 / Accepted: 7 October 2020 / Published: 9 October 2020
(This article belongs to the Special Issue Kidney Inflammation, Injury and Regeneration 2020)

Abstract

:
In the present study, we investigated the effects of xanthine oxidase (XO) inhibition on cholesterol-induced renal dysfunction in chronic kidney disease (CKD) mice, and in low-density lipoprotein (LDL)-treated human kidney proximal tubule epithelial (HK-2) cells. ApoE knockout (KO) mice underwent uninephrectomy to induce CKD, and were fed a normal diet or high-cholesterol (HC) diet along with the XO inhibitor topiroxostat (1 mg/kg/day). HK-2 cells were treated with LDL (200 µg/mL) and topiroxostat (5 µM) or small interfering RNA against xanthine dehydrogenase (siXDH; 20 nM). In uninephrectomized ApoE KO mice, the HC diet increased cholesterol accumulation, oxidative stress, XO activity, and kidney damage, while topiroxostat attenuated the hypercholesterolemia-associated renal dysfunction. The HC diet induced cholesterol accumulation by regulating the expressions of genes involved in cholesterol efflux (Nr1h3 and Abca1) and synthesis (Srebf2 and Hmgcr), which was reversed by topiroxostat. Topiroxostat suppressed the expressions of genes related to hypercholesterolemia-associated inflammation and fibrosis in the unilateral kidney. LDL stimulation evoked changes in the cholesterol metabolism, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and NF-κB pathways in HK-2 cells, which were mitigated by XO inhibition with topiroxostat or siXDH. These findings suggest that XO inhibition exerts renoprotective effects against hypercholesterolemia-associated kidney injury. XO could be a novel therapeutic target for hypercholesterolemia-associated kidney injury in uninephrectomized patients.

1. Introduction

Compared to people with normal cholesterol levels, those with high cholesterol levels are 1.5 times more likely to develop kidney dysfunction [1,2]. Individuals with metabolic syndrome who serve as kidney donors reportedly show a higher incidence of post-donation kidney disease due to dyslipidemia and obesity compared to normal donors [3,4]. These findings suggest that abnormal cholesterol metabolism independently increases the risk of chronic kidney disease.
Dyslipidemia may directly affect the kidney by causing deleterious renal lipid disturbances, and indirectly affect the kidney through systemic inflammation, oxidative stress and vascular injury [5,6]. We previously reported that high concentrations of uric acid synthesis metabolites lead to the generation of reactive oxygen species (ROS), which promotes hypercholesterolemia with cholesterol accumulation in hepatocytes and incites atherosclerosis in apolipoprotein E (ApoE)-deficient mice [7]. However, the effects of cholesterol on the kidneys have not been confirmed.
In a unilateral kidney, a high-fat diet alters the expressions of genes involved in the cytoskeletal remodeling, fibrosis, and oxidative stress pathways. This suggests that the high-fat diet has synergistic effects that promote gene expression changes related to kidney damage [8]. Additionally, in animal experiments, unilateral kidney dyslipidemia is associated with the exacerbation of kidney damage, characterized by decreased kidney function, vasodilation, fibrosis, oxidative stress, and ER stress, despite normal body weight [9]. These findings suggest that kidney lipid accumulation and lipid toxicity play important roles in the pathogenesis of kidney damage, and are associated with a higher risk of kidney damage in unilateral kidneys.
It has been postulated that oxidative stress—derived from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mitochondrial oxidase, and xanthine oxidase (XO)—is involved in renal lipid disturbances [10]. Notably, high cholesterol levels activate XO and lead to excessive ROS formation, resulting in tissue damage, such as inflammation and atherosclerosis [11,12]. Consistently, XO inhibitors exhibit pronounced protective effects against vascular injuries, inflammatory diseases, and tissue damage [13,14]. XO inhibitors can also inhibit the expression of pro-inflammatory proteins. Therefore, XO inhibitors have potential for use as therapeutic drugs that reduce oxidative stress [15]. However, the XO inhibitor allopurinol does not inhibit renal dysfunction in patients with chronic kidney disease (CKD) and high risk of progression [16].Thus, the effect of XO inhibitors in terms of kidney protection remains controversial.
In the present study, we investigated the correlation between cell injury and non-oxidized LDL-induced ROS in vitro, as well as the effects of a high-cholesterol (HC) diet and hypercholesterolemia on lipid accumulation and renal tubule damage in vivo using a unilateral kidney model. We further aimed to identify potential signaling pathways that could be affected by lipid accumulation-induced xanthine oxidase and ROS under a CKD associated with hypercholesterolemia.

2. Results

2.1. Hypercholesterolemia Aggravates Renal Function Through Increased Kidney Lipid Accumulation, Xanthine Oxidase Activity, and Oxidative Stress

PAS staining confirmed that the high-cholesterol (HC) diet led to renal tubular damage in the unilateral kidney (Figure 1A). The HC diet yielded increased serum blood urea nitrogen (BUN) and creatinine, which were highest with HC+uninephrectomy (UN) group (Figure 1B–C). The XO inhibitor topiroxostat (TP) attenuated this kidney dysfunction (Figure 1A–C). Kidney weight was increased in uninephrectomized mice, whereas reduced by TP treatment (Figure 1D). In both sham-operated and UN mice, HC diet yielded increased serum total cholesterol (TC), low-density lipoprotein (LDL), and triglycerides (TG), and TP treatment restored these levels (Figure 1E–G).
Compared to normal control (NC), HC and HC+UN yielded increased lipid droplets in the kidney, showing higher levels with HC+UN versus HC (Figure 1H). Kidney TC was higher with HC and HC+UN versus NC, and was reduced by TP in the HC+UN+TP group (Figure 1I). Free cholesterol did not differ among groups. HC and HC+UN showed trends of increased kidney cholesterol esters (Figure 1J,K). TP decreased kidney cholesterol accumulation, consistent with decreased serum TC, LDL, and TG. The HC diet significantly elevated XO activity, dichlorodihydrofluorescein diacetate (DCFDA), and H2O2 excretion in kidney tissue, which were higher with HC+UN versus HC. TP decreased the increased XO activity and intracellular oxidative stress markers (Figure 1L–N).

2.2. Effects of Hypercholesterolemia on Genes Related to Cellular Cholesterol Transport and Synthesis in the Unilateral Kidney

Compared to NC, the HC diet groups exhibited increased mRNA expression of genes related to cholesterol efflux (Nr1h3 and Abca1), LDL and modified LDL uptake (Ldlr, Msr1, and Scarb1), TG synthesis (Srebf1), and cholesterol synthesis (Srebf2 and Hmgcr) (Figure 2A–I). HC+UN yielded decreased Nr1h3 and Abca1 (Figure 2A,B), increased Msr1 and Scarb1, and decreased Ldlr expression (Figure 2C–E). Lcat expression was increased with the HC diet versus normal diet but did not differ between HC and HC+UN (Figure 2F). HC+UN yielded increased Srebf1, Srebf2, and Hmgcr expression (Figure 2G–I). TP treatment (HC+UN+TP) increased Nr1h3 and Abca1 expression, and decreased Srebf1, Srebf2, and Hmgcr expression (Figure 2A,B,G–I). The HC diet led to increased ABCA1 and HMGCR protein levels, which were higher with HC+UN versus HC. LXRα protein levels were not altered by HC diet (Figure 2J–L). Overall, TP treatment yielded increased cholesterol efflux gene expression and reduced cholesterol synthesis gene expression (Figure 2).

2.3. Effects of LDL on Cholesterol Metabolism and Oxidative Stress in HK-2 Cells

LDL increased NR1H3, ABCA1, and HMGCR expression in human kidney proximal tubule epithelial (HK-2) cells, without affecting LDLR, SREBF1, or SREBF2. TP decreased only HMGCR expression (Figure 3A–F). LDL increased intracellular ROS over the basal level, which peaked at 30 min (Figure 3G), with elevated H2O2 level and ROS-dependent DCF fluorescence intensity. TP reduced cellular ROS, similar to the positive control NAC (Figure 3H–I).
Using siXDH, we evaluated how XO knock-down influenced cholesterol-related metabolism. LDL increased XDH expression in HK-2 cells (Figure 4G), and induced expression of the cholesterol transport genes NR1H3 and ABCA1, but not LDLR. The siXDH reduced transport gene expression in LDL-treated HK-2 cells, to a greater extent than XO inhibitor (Figure 4A–C). XO deficiency regulated cholesterol synthesis genes upon LDL stimulation. LDL stimulation increased expressions of SREBF1, SREBF2, and HMGCR, while siXDH suppressed the increased expressions of SREBF2 and HMGCR (Figure 4D–F).
We examined mRNA expressions of subunits of the ROS generation enzyme NADPH oxidase. LDL-treated HK-2 cells exhibited increased mRNA expressions of NOX1, NOX2, p22phox, and p47phox. TP inhibited these increased expressions, similar to NAC (Figure 3J–M). siXDH transfection also reduced expression of NOX1, NOX2, p22phox, and p47phox (Figure 4H–K).

2.4. XO Inhibition Reduces Hypercholesterolemia-Associated Kidney Inflammation and Fibrosis in CKD Mice

We evaluated the inflammatory responses to high cholesterol and oxidative stress in the kidney of a CKD model. The HC diet increased inflammation cytokines (e.g., TNF-α) and the macrophage monocyte marker CD68, which were higher with HC+UN versus HC (Figure 5A). Expressions of the inflammation-related genes Il-1β, Il-18, and Nlrp3 were also increased with HC+UN versus HC. TP reduced inflammation-related gene expression in uninephrectomized mice (Figure 5B–D). Compared to NC, HC groups showed progression in the fibrosis of glomeruli and interstitium, which was greatest with HC+UN, and was reduced by TP (Figure 5E). Compared to HC, HC+UN yielded increased Acta2, Col1, and Fn1 expressions (Figure 5F–I). Fibronectin and α-SMA protein expressions were not significantly increased in the HC+UN group (Figure 5J,K).
Finally, we evaluated the effects of LDL on the NF-κB pathway [17], downstream of TNF-α. LDL-stimulated HK-2 cells showed increased NF-κB p50 and NF-κB p65 levels, which were decreased by TP (Figure 6A–B). We also investigated the NF-κB inhibitors JSH23 and BAY11-7082. In LDL-treated HK-2 cells, JSH23 treatment significantly decreased NF-κB p65, and IL-1β, but did not affect NLRP3 and NF-κB p50 (Figure 6C–F), while BAY11-7082 treatment reduced NF-κB p50, IL-1β, and NLRP3 levels, but did not affect NF-κB p65 (Figure 6G–J).

3. Discussion

The present results demonstrated that XO inhibition significantly reduced hypercholesterolemia-associated kidney inflammation and fibrosis in uninephrectomized ApoE KO mice. In vitro experiments revealed that XO inhibition reduced LDL-induced oxidative stress and cholesterol synthesis. The HC diet induced cholesterol accumulation by regulating the expression of genes related to cholesterol efflux and synthesis. Additionally, hypercholesterolemia significantly increased XO activity and NADPH-dependent ROS generation, thus inducing kidney inflammation and fibrosis. LDL stimulation evoked changes in the cholesterol metabolism, NADPH oxidase, and NF-κB pathways in HK-2 cells. XO inhibition modulated the hypercholesterolemia-induced changes in the expression of genes related to cholesterol transport and synthesis. XO inhibition by topiroxostat attenuated inflammation and fibrosis in the unilateral kidney through inhibition of the NF-κB pathway.
Patients with CKD exhibit various lipid abnormalities [18], and abnormal lipid metabolism is associated with kidney disease progression [19,20]. However, the mechanism of lipid-induced kidney damage is not fully understood. In the present study, we used ApoE KO mice with unilateral nephrectomy as a model to evaluate the effects of hypercholesterolemia on CKD progression. Hypercholesterolemia aggravated renal function in the uninephrectomized ApoE KO mice by increasing kidney lipid accumulation. Moreover, these lipid abnormalities were associated with increases of factors mediating kidney injury, such as XO and oxidative stress.
Our results demonstrated that cholesterol accumulation in uninephrectomized mice was induced by upregulation of genes related to cholesterol synthesis, such as Srebf2 and Hmgcr, and downregulation of efflux-related genes, such as Abca1 and Nr1h3, upstream of ABCA1. Cholesterol homeostasis is regulated by multiple pathways, including intracellular cholesterol uptake, synthesis, and efflux actions [21]. Inflammatory stress promotes reduction of cholesterol efflux through the ABCA1 pathway, leading to lipid accumulation in the kidney [22]. ApoE promotes cholesterol efflux through the ABCA1 and ABCG1 cell surface transporters, which facilitate the efflux of phospholipids and cholesterol onto lipid-poor apolipoproteins [23]. The ABCA1 transporter facilitates the efflux of cellular phospholipids and cholesterol to acceptors, such as ApoA-I and ApoE [24]. Selective inactivation of macrophage ABCA1 yields substantially increased cholesterol accumulation in mice [25,26]. Our present results showed that the HC diet caused upregulated expression of both cholesterol synthesis and efflux genes. Furthermore, uninephrectomy plus hypercholesterolemia attenuated the increase of cholesterol efflux genes, while upregulating the increase of cholesterol synthesis genes. It is not yet known why uninephrectomy had different effects on the expression of genes related to cholesterol metabolism. However, our findings suggest that hypercholesterolemia-associated genes contributed to cholesterol accumulation in the kidney, and may potentially play a role in the dysfunction of the unilateral kidney.
The ABCA1 protein level differed from mRNA expression in the unilateral kidney with high cholesterol. The ABCA1 membrane protein rapidly responds to increased cholesterol, and the ABCA1 protein level is independent of its transcription [27]. Cholesterol accumulation inhibits ABCA1 degradation and ubiquitination by decreasing the proteasomal degradation [28]. In our study, the decrease of Abca1 mRNA may have been associated with the reduced intracellular cholesterol efflux, and thus with the increased cholesterol accumulation in the kidney.
Abnormal lipid metabolism induces monocyte foam cells, and this change is more prominent in patients with kidney dysfunction [29]. Alterations in lipoprotein metabolism promote the production of ROS, such as hydrogen peroxide; however, the effect on intracellular cholesterol has not been clearly demonstrated. Since increased serum LDL level is a representative marker of dyslipidemia, we stimulated renal tubular cells with LDL to examine the molecular changes in cholesterol metabolism and inflammation. LDL stimulation increased the mRNA expression of NR1H3, ABCA1, LDLR, SREBF2, and HMGCR in HK-2 cells. These changes are consistent with our observations in the animal model, except for the expression of SREBF1, which is involved in TG synthesis. These findings suggest that the renal tubular cell damage is also mediated by the lipid accumulation associated with changes in the expression of genes related to cholesterol transport and synthesis.
XO is a key enzyme of the purine pathway, producing uric acid through various oxidized purines [30]. Recent studies demonstrate that XO plays a role as an ROS-producing enzyme, aggravating inflammation, atherosclerosis, and chronic disease [31]. XO activity is increased in obesity, and XO inhibitors regulate the inflammatory process by inhibiting production of ROS and uric acid [32,33]. We previously demonstrated that XO inhibition could decrease cancer cell migration and ROS generation [10]. In our present study, we found that XO activity and gene expression were increased in kidneys with hypercholesterolemia, and in LDL-treated HK-2 cells. This is the first report of cholesterol directly leading to increased XO enzyme activity in the kidney. We further found that XO inhibition improved hypercholesterolemia-associated kidney damage by modulating the expression of genes related to cholesterol metabolism and the progression of inflammation and fibrosis in a unilateral kidney. Overall, our findings suggest that XO is a promising treatment target for hypercholesterolemia-associated kidney injury in uninephrectomized patients.
Expression of NOX1, NOX2, and NOX4 in the kidney mediates oxidative stress and promotes vascular inflammation, dysfunction, and fibrosis in CKD [34]. NADPH oxidases of the kidney exhibit a distinct cellular localization and are activated by various stimuli, including LDL [35]. Our results demonstrated that hypercholesterolemia and LDL increased oxidative stress in kidney tissue and tubule cells, and that XO activity was associated with oxidative stress markers and increased expression of NADPH-related genes. XO inhibition reduced the expression of NOX1 and NOX2, but not NOX4 (data not shown), showing antioxidant effects similar to with NAC. Transfection with siXDH had the same effect as XO inhibitor in HK-2 cells. These results revealed that XO inhibition controlled NOX activity, thus suppressing oxidative stress and reducing renal damage.
The inflammatory process exacerbates lipid accumulation in the kidney by translocating plasma lipids to the kidney [36]. A high-fat diet activates the inflammatory response by increasing TNF-α expression in the kidney, thus causing kidney damage in obese humans and animal models [37,38]. XO activity is elevated in inflammation, and XO inhibition suppresses inflammation and oxidative stress in macrophages [14]. Treatment with XO inhibitors reportedly attenuates inflammation and fibrosis in animal models of atherosclerosis and nonalcoholic steatohepatitis [39]. Here we found that a HC diet led to increased TNF-α and CD68 in the unilateral kidney, which was downregulated after XO inhibition. These results showed that the mechanism of hypercholesterolemia-associated kidney damage is closely related to inflammation, and that the damage could be suppressed by XO inhibition.
Oxidative stress stimulates inflammatory cells to activate the NF-κB pathway through an intracellular signaling system, thus mediating inflammation [40]. In cells, oxidative stress induces NLRP3 activity, leading to inflammation and apoptosis, along with Caspase-1 activation. Obesity and metabolic syndrome induce NLRP3 inflammatory activation, which weakens phospholipid degradation, leading to kidney damage [41]. In this study, hypercholesterolemia increased NLRP3 and TNF-α, which is one of the most potent inducers of NF-κB. In vitro experiments demonstrated that the NF-κB pathway was an inflammatory mechanism of dyslipidemia-associated kidney damage. LDL stimulation increased the activity of the NF-κB pathway and NLRP3, whereas XO inhibition affected the NF-κB pathway by decreasing phosphorylated NF-κB p65 and NF-κB p50 in HK-2 cells. We further demonstrated that the NF-κB inhibitors JSH23 and BAY11-7028 had effects on NLRP3 similar to those of XO inhibition. This supports the theory that NF-κB is a main pathway of hypercholesterolemia-associated kidney damage.
In conclusion, our present data suggested that XO inhibition has renoprotective effects against hypercholesterolemia-associated kidney injury. This protection from XO inhibition was mediated by regulation of cholesterol metabolism, decreasing NADPH-dependent ROS generation, and reduction of inflammation through the NF-κB pathway. XO could be a novel therapeutic target for hypercholesterolemia-associated kidney disease in uninephrectomized patients.

4. Materials and Methods

4.1. Animals, Diets, and Specimen Collections

Male ApoE KO mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) at the age of 8 weeks. All animal experiments were approved and performed according to the regulations of the Kyungpook National University Animal Care and Use Committee (KNU-2018-0042, date; 08/03/2018). For 12 weeks, animals were fed normal control diet containing 20.3% protein, 5% fat, and 66% carbohydrate or a high-fat high-cholesterol diet (HC, diet D12336; Research Diets, New Brunswick, NJ, USA) containing 16.0% fat, 1.25% cholesterol, and 0.5% sodium cholic acid.
We randomized the eight-week-old ApoE KO mice into groups that did or did not receive topiroxostat (TP; 1 mg per kg body weight) treatment, and that did or did not undergo uninephrectomy (UN) surgery. There were a total of five groups: NC (n = 5), fed a normal control diet; HC (n = 6), fed a high-cholesterol diet; HC+TP (n = 6), fed a high-cholesterol diet with TP; HC+UN (n = 8), fed a high-cholesterol diet and received uninephrectomy surgery; and HC+UN+TP (n = 8), fed a high-cholesterol diet with TP and received uninephrectomy surgery. All mice that did not undergo uninephrectomy were sham operated. TP was administered by oral gavage for 4 weeks before the end of the experiment.
Uninephrectomy was performed as described previously [42]. For uninephrectomy, after mice were anesthetized with 3–5% isoflurane, the left kidney was surgically removed via a left incision on the back. The adrenal gland was carefully freed from the upper pole of the renal capsule before removed the left kidney. The incision was closed with sutures. In sham surgery, the kidney was manipulated without ablation. At 12 weeks after surgery, all mice were anesthetized and then sacrifice, and kidneys were harvested for the analyses. Half of the kidneys were stored at −80 °C for molecular analysis and the other half was fixed with 4% paraformaldehyde for histological analysis.

4.2. Serum Chemistry

At the end of the experimental period, blood samples from each mouse were collected into tubes by cardiac puncture. The blood was sampled into ethylenediaminetetraacetic acid-free bottles for serum separation. The blood urea nitrogen (BUN), creatinine (Cr), uric acid, total cholesterol (TC), low-density lipoprotein (LDL) and triglycerides level in the serum were measured by GCLabs (Yongin, Korea) using the Cobas 8000 modular analyzer system (Roche, Basel, Switzerland).

4.3. Histopathology

To detect kidney injury, the fixed right kidney was dehydrated in ethanol and embedded in paraffin. Kidney tissue blocks were cut into 2-μm-thick sections and subjected to hematoxylin and eosin (H&E) staining, periodic acid Schiff (PAS) staining, and Masson’s trichrome staining. For immunohistochemical analysis of kidney tissues, we used the following antibodies: mouse monoclonal against CD68 (ED1; 1:100; Abcam, Cambridge, MA, USA) and rabbit polyclonal against tumor necrosis factor-α (TNF-α; 1:200; Abcam). Next, secondary antibody was performed using HRP-conjugated polyclonal goat anti-rabbit IgG P0447 or goat anti-mouse IgG p0448 (Dako, Glostrup, Denmark) for 1 h. The sections were visualized using 3,3-diaminobenzidine (DAB; DAKO ChemMate Detection Kit) and counterstained with Mayer’s hematoxylin.

4.4. Oil Red O Staining

Fixed frozen kidney tissue was cut into 6-μm-thick sections, and subjected to Oil Red O (Sigma-Aldrich, Saint Louis, MO, USA) staining following the manufacturer’s protocol. After the sections were rinsed in distilled water and 60% isopropanol for 1 min, the sections were stained with Oil red O for 15 min. and then rinsed in 60% isopropanol and distilled water each for 1 min. Counterstaining was stained with hematoxylin for 1 min.

4.5. Cell Treatments

Human renal proximal tubule epithelial cells (HK-2 cells) were purchased from the Korean Cell Line Bank (KCLB, Seoul, South Korea). The cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum, and 100 units/mL penicillin and 100 μg/mL streptomycin antibiotic mixture at 37 °C in 5% CO2 and 95% air. The Cells were pretreated with topiroxostat (TP), xanthine oxidase inhibitor (5 or 10 µM), and 5 mM N-acetylcysteine (NAC) (Sigma-Aldrich) for 1 h, and stimulated with LDL (200 µg/mL) for 30 min to induce lipotoxicity.

4.6. Hydrogen Peroxide Determination

H2O2 levels were measured using the Amplex Red Hydrogen Peroxide Assay Kit (Molecular Probes, Invitrogen, Eugene, OR, USA), following the manufacturer’s protocol. To detect H2O2 released from kidney tissue and treated HK cells, cell lysate or culture media were reacted with the Amplex Red Reagent in the presence of horseradish peroxidase to produce the red-fluorescent oxidation product resorufin. The fluorescence of resorufin was determined at 530nm excitation and 590 nm emission using a fluorescence microplate reader (Molecular Devices, Sunnyvale, CA, USA). The concentrations of H2O2 were calculated using standard curves. The loading buffer was measured and subtracted from each value in order to exclude background fluorescence.

4.7. Intracellular ROS Measurement

Intracellular ROS generation was measured using 2′,7′-dichlorofluorescein diacetate (DCF-DA). HK-2 cells and kidney tissues were stained for 40 min with 10 µM 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA; Molecular Probes) in a black 96-well plate. DCF-DA is hydrolyzed by esterases to dichlorofluorescein (DCF), which is trapped within the cell. Then cellular oxidants oxidize this non-fluorescent molecule to fluorescent dichlorofluorescein (DCF). Fluorescence signal intensity was measured at 480 nm excitation and 520 nm emission using a fluorescence microplate reader (Molecular Devices). The value of the fluorescence signal was expressed as a percentage of the control.

4.8. Determination of Intracellular Total Cholesterol

From the kidney tissues of ApoE mice, we extracted cellular lipids by chloroform:methanol extraction (4:2:3, chloroform:methanol:water). Total cholesterol levels were determined using a commercially available kit (Cell Biolabs Inc., San Diego, CA, USA) following the manufacturer’s protocol.

4.9. Transfection of HK-2 with XDH siRNA

ON-TARGETplus SMARTpool siRNAs used for silencing expression of human XDH genes (ID:7498) and non-targeting (negative control) siRNA were purchased from Dharmacon (Chicago, IL, USA). Four target sequences in human XDH are 5′- AGA GUG AGG UUG ACA AGU U -3′, 5′- GGA GUA ACA UAA CUG GAA U -3′, 5′- UAG AGG AGC UAC ACU AUU C -3′ and 5′- ACA CGG AGA UUG GCA UUG A -3′. siRNAs were used at a concentration of 20 nM. Transfection was performed using Opti-MEM™ transfection medium and Lipofectamine™ (both from Invitrogen, Paisley, UK). One day prior to transfection, HK-2 cells were seeded and cultured to reach 30–40% confluence on the following day. RNAi duplexes for XDH were mixed with Lipofectamine, forming a transfection complex that was added to the plated cells. After 24 h of incubation, the medium was replaced with RPMI, and cells were starved for 6 h. Transfected cells were used for quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).

4.10. Quantitative Real-Time Polymerase Chain Reactions

Quantitative real-time RT-PCR analysis was performed as described previously [7]. Total RNA was extracted from cell lysates using TRIreagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the provider’s instructions. One microgram of total RNA was reverse transcribed to cDNA using the PrimeScript cDNA synthesis kit (TaKaRa, Otsu, Japan). Quantitative real-time RT-PCR was performed on the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster city, CA, USA) using the SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The results were analyzed using the comparative Ct method for relative quantification of gene expression. The primer sets used in this study are listed in Table 1.

4.11. Immunoblot Analysis

Protein concentration was measured using Bradford’s method in lysates of treated HK2 cells and tissues. Total protein (20 µg) was separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked with 10% skim milk for 1 h at room temperature, and incubated overnight at 4 °C with primary antibodies. The membrane was incubated with HRP-conjugated polyclonal goat anti-rabbit IgG P0447 or goat anti-mouse IgG p0448 (Dako, Glostrup, Denmark) as the secondary antibody for 1 h and detected using advanced ECL reagents (Amersham Bioscience, Piscataway, NJ, USA). The target protein bands were normalized to that of GAPDH. Expression levels were estimated using Scion Image software (Scion, Frederick, MD, USA). The primary antibodies that detect proteins are listed in Table 2.

4.12. Statistical Analysis

Data are presented as mean ± SEM. Statistical analyses were performed using GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA, USA). The difference among the groups was analyzed using a one-way nonparametric ANOVA followed by Tukey’s multiple comparison test. A p value of <0.05 was considered statistically significant.

Author Contributions

Conceptualization, Y.-J.K., J.-H.C. and Y.-L.K.; Formal analysis, Y.-J.K., S.-H.O., C.-D.K., S.-H.P., J.-H.C. and Y.-L.K.; Funding acquisition, Y.-J.K. and Y.-L.K.; Investigation, Y.-J.K., S.-H.O., J.-S.A. and J.-M.Y.; Methodology, Y.-J.K.; Visualization, Y.-J.K. and S.-H.O.; Writing—original draft, Y.-J.K.; Writing—review & editing, J.-H.C. and Y.-L.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1A6A3A01008277, 2020R1I1A1A01055554, 2020R1I1A3068253).

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ABCA1ATP Binding Cassette Subfamily A Member 1
ABCG1ATP-binding cassette super-family G Member 1
ApoE KOApolipoprotein E Knockout
BUNBlood urea nitrogen
CD68Cluster of Differentiation 68
CKDChronic kidney disease
DCFDADichlorodihydrofluorescein diacetate
HCHigh-cholesterol
HMGCR3-Hydroxy-3-Methylglutaryl-CoA Reductase
Il-1Interleukin-1
LCATLecithin-cholesterol acyltransferase
LDLLow-density lipoprotein
LDLRLow density lipoprotein receptor
LXRαLiver X receptor α
MSR1Macrophage scavenger receptor types I
NR1H3Nuclear receptor subfamily 1 group H member 3
NADPHNicotinamide adenine dinucleotide phosphate
NF-κBNuclear Factor-kappaB
NLRP3NOD-, LRR- and pyrin domain-containing protein 3
NOXNADPH oxidase
PASPeriodic acid-Schiff
ROSReactive oxygen species
siXDHSmall interfering RNA against XDH
SCARB1Scavenger receptor class B type 1
SREBFSterol regulatory element binding transcription factor
TC Total cholesterol
TGTriglyceride
TNF-αTumor necrosis factor α
TPTopiroxostat
XOXanthine oxidase
α-SMAAlpha-smooth muscle actin

References

  1. Gelber, R.P.; Kurth, T.; Kausz, A.T.; Manson, J.E.; Buring, J.E.; Levey, A.S.; Gaziano, J.M. Association between body mass index and CKD in apparently healthy men. Am. J. Kidney Dis. 2005, 46, 871–880. [Google Scholar] [CrossRef] [PubMed]
  2. Reiss, A.B.; Voloshyna, I.; De Leon, J.; Miyawaki, N.; Mattana, J. Cholesterol Metabolism in CKD. Am. J. Kidney Dis. 2015, 66, 1071–1082. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Locke, J.E.; Reed, R.D.; Massie, A.; MacLennan, P.A.; Sawinski, D.; Kumar, V.; Mehta, S.; Mannon, R.B.; Gaston, R.; Lewis, C.E.; et al. Obesity increases the risk of end-stage renal disease among living kidney donors. Kidney Int. 2017, 91, 699–703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Muzaale, A.D.; Massie, A.B.; Wang, M.C.; Montgomery, R.A.; McBride, M.A.; Wainright, J.L.; Segev, D.L. Risk of end-stage renal disease following live kidney donation. JAMA 2014, 311, 579–586. [Google Scholar] [CrossRef] [PubMed]
  5. Amiya, E. Interaction of hyperlipidemia and reactive oxygen species: Insights from the lipid-raft platform. World J. Cardiol. 2016, 8, 689–694. [Google Scholar] [CrossRef] [PubMed]
  6. Bobulescu, I.A. Renal lipid metabolism and lipotoxicity. Curr. Opin. Nephrol. Hypertens. 2010, 19, 393–402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Ryu, H.M.; Kim, Y.J.; Oh, E.J.; Oh, S.H.; Choi, J.Y.; Cho, J.H.; Kim, C.D.; Park, S.H.; Kim, Y.L. Hypoxanthine induces cholesterol accumulation and incites atherosclerosis in apolipoprotein E-deficient mice and cells. J. Cell Mol. Med. 2016, 20, 2160–2172. [Google Scholar] [CrossRef] [Green Version]
  8. Gai, Z.; Hiller, C.; Chin, S.H.; Hofstetter, L.; Stieger, B.; Konrad, D.; Kullak-Ublick, G.A. Uninephrectomy augments the effects of high fat diet induced obesity on gene expression in mouse kidney. Biochim. Biophys. Acta 2014, 1842, 1870–1878. [Google Scholar] [CrossRef] [Green Version]
  9. Bro, S.; Bentzon, J.F.; Falk, E.; Andersen, C.B.; Olgaard, K.; Nielsen, L.B. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J. Am. Soc. Nephrol. 2003, 14, 2466–2474. [Google Scholar] [CrossRef] [Green Version]
  10. Oh, S.H.; Choi, S.Y.; Choi, H.J.; Ryu, H.M.; Kim, Y.J.; Jung, H.Y.; Cho, J.H.; Kim, C.D.; Park, S.H.; Kwon, T.H.; et al. The emerging role of xanthine oxidase inhibition for suppression of breast cancer cell migration and metastasis associated with hypercholesterolemia. FASEB J. 2019, 33, 7301–7314. [Google Scholar] [CrossRef]
  11. Gwinner, W.; Scheuer, H.; Haller, H.; Brandes, R.P.; Groene, H.J. Pivotal role of xanthine oxidase in the initiation of tubulointerstitial renal injury in rats with hyperlipidemia. Kidney Int. 2006, 69, 481–487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Kataoka, H.; Yang, K.; Rock, K.L. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung. Eur. J. Pharmacol. 2015, 746, 174–179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Pacher, P.; Nivorozhkin, A.; Szabó, C. Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 2006, 58, 87–114. [Google Scholar] [CrossRef]
  14. Nomura, J.; Busso, N.; Ives, A.; Matsui, C.; Tsujimoto, S.; Shirakura, T.; Tamura, M.; Kobayashi, T.; So, A.; Yamanaka, Y. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci. Rep. 2014, 4, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Dandona, P.; Ghanim, H.; Brooks, D.P. Antioxidant activity of carvedilol in cardiovascular disease. J. Hypertens. 2007, 25, 731–741. [Google Scholar] [CrossRef] [PubMed]
  16. Badve, S.V.; Pascoe, E.M.; Tiku, A.; Boudville, N.; Brown, F.G.; Cass, A.; Clarke, P.; Dalbeth, N.; Day, R.O.; de Zoysa, J.R.; et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N. Engl. J. Med. 2020, 382, 2504–2513. [Google Scholar] [CrossRef] [PubMed]
  17. Janabi, M.; Yamashita, S.; Hirano, K.; Sakai, N.; Hiraoka, H.; Matsumoto, K.; Zhang, Z.; Nozaki, S.; Matsuzawa, Y. Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol. 2000, 20, 1953–1960. [Google Scholar] [CrossRef] [Green Version]
  18. Cases, A.; Coll, E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int. Suppl. 2005, 68, S87–S93. [Google Scholar] [CrossRef] [Green Version]
  19. Moorhead, J.; El-Nahas, M.; Chan, M.; Varghese, Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982, 320, 1309–1311. [Google Scholar] [CrossRef]
  20. Scarpioni, R.; Ricardi, M.; Albertazzi, V.; Melfa, L. Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World J. Nephrol. 2012, 1, 184–194. [Google Scholar] [CrossRef] [Green Version]
  21. Afonso, M.S.; Machado, R.M.; Lavrador, M.S.; Quintao, E.C.R.; Moore, K.J.; Lottenberg, A.M. Molecular Pathways Underlying Cholesterol Homeostasis. Nutrients 2018, 10, 760. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Ruan, X.Z.; Moorhead, J.F.; Fernando, R.Y.; Wheeler, D.C.; Powis, S.H. PPAR agonists protect mesangial cells from interleukin 1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J. Am. Soc. Nephrol. 2003, 14, 593–600. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Gelissen, I.C.; Harris, M.; Rye, K.A.; Quinn, C.; Brown, A.J.; Kockx, M.; Cartland, S.; Packianathan, M.; Kritharides, L.; Jessup, W. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arter. Thromb. Vasc. Biol. 2006, 26, 534–540. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Brooks-Wilson, A.; Marcil, M.; Clee, S.M.; Zhang, L.-H.; Roomp, K.; van Dam, M.; Yu, L.; Brewer, C.; Collins, J.A.; Molhuizen, H.O. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999, 22, 337. [Google Scholar] [CrossRef] [PubMed]
  25. Zuo, Y.; Yancey, P.; Castro, I.; Khan, W.N.; Motojima, M.; Ichikawa, I.; Fogo, A.B.; Linton, M.F.; Fazio, S.; Kon, V. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arter. Thromb. Vasc. Biol. 2009, 29, 1277–1282. [Google Scholar] [CrossRef] [Green Version]
  26. Joyce, C.; Freeman, L.; Brewer, H.B., Jr.; Santamarina-Fojo, S. Study of ABCA1 function in transgenic mice. Arter. Thromb. Vasc. Biol. 2003, 23, 965–971. [Google Scholar] [CrossRef]
  27. Hsieh, V.; Kim, M.J.; Gelissen, I.C.; Brown, A.J.; Sandoval, C.; Hallab, J.C.; Kockx, M.; Traini, M.; Jessup, W.; Kritharides, L. Cellular cholesterol regulates ubiquitination and degradation of the cholesterol export proteins ABCA1 and ABCG1. J. Biol. Chem. 2014, 289, 7524–7536. [Google Scholar] [CrossRef] [Green Version]
  28. Wellington, C.L.; Walker, E.K.; Suarez, A.; Kwok, A.; Bissada, N.; Singaraja, R.; Yang, Y.-Z.; Zhang, L.-H.; James, E.; Wilson, J.E. ABCA1 mRNA and Protein Distribution Patterns Predict Multiple Different Roles and Levels of Regulation. Regulation 2002, 82, 273–283. [Google Scholar] [CrossRef] [Green Version]
  29. Eom, M.; Hudkins, K.L.; Alpers, C.E. Foam cells and the pathogenesis of kidney disease. Curr. Opin. Nephrol. Hypertens. 2015, 24, 245–251. [Google Scholar] [CrossRef]
  30. Kushiyama, A.; Tanaka, K.; Hara, S.; Kawazu, S. Linking uric acid metabolism to diabetic complications. World J. Diabetes 2014, 5, 787–795. [Google Scholar] [CrossRef]
  31. Nomura, J.; Busso, N.; Ives, A.; Tsujimoto, S.; Tamura, M.; So, A.; Yamanaka, Y. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS ONE 2013, 8, e75527. [Google Scholar] [CrossRef] [PubMed]
  32. Klisic, A.; Kocic, G.; Kavaric, N.; Jovanovic, M.; Stanisic, V.; Ninic, A. Body mass index is independently associated with xanthine oxidase activity in overweight/obese population. Eat. Weight Disord. 2020, 25, 9–15. [Google Scholar] [CrossRef] [PubMed]
  33. Ives, A.; Nomura, J.; Martinon, F.; Roger, T.; LeRoy, D.; Miner, J.N.; Simon, G.; Busso, N.; So, A. Xanthine oxidoreductase regulates macrophage IL1beta secretion upon NLRP3 inflammasome activation. Nat. Commun. 2015, 6, 6555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Honda, T.; Hirakawa, Y.; Nangaku, M. The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract. 2019, 38, 414–426. [Google Scholar] [CrossRef] [Green Version]
  35. Ratliff, B.B.; Abdulmahdi, W.; Pawar, R.; Wolin, M.S. Oxidant Mechanisms in Renal Injury and Disease. Antioxid. Redox Signal. 2016, 25, 119–146. [Google Scholar] [CrossRef] [Green Version]
  36. Ruan, X.Z.; Moorhead, J.F.; Varghese, Z. Lipid redistribution in renal dysfunction. Kidney Int. 2008, 74, 407–409. [Google Scholar] [CrossRef] [Green Version]
  37. Laurencikiene, J.; van Harmelen, V.; Arvidsson Nordstrom, E.; Dicker, A.; Blomqvist, L.; Naslund, E.; Langin, D.; Arner, P.; Ryden, M. NF-kappaB is important for TNF-alpha-induced lipolysis in human adipocytes. J. Lipid Res. 2007, 48, 1069–1077. [Google Scholar] [CrossRef] [Green Version]
  38. Wang, Z.; Huang, W.; Li, H.; Tang, L.; Sun, H.; Liu, Q.; Zhang, L. Synergistic action of inflammation and lipid dysmetabolism on kidney damage in rats. Ren. Fail. 2018, 40, 175–182. [Google Scholar] [CrossRef]
  39. Mizuno, Y.; Yamamotoya, T.; Nakatsu, Y.; Ueda, K.; Matsunaga, Y.; Inoue, M.K.; Sakoda, H.; Fujishiro, M.; Ono, H.; Kikuchi, T.; et al. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice. Int. J. Mol. Sci. 2019, 20, 4680. [Google Scholar] [CrossRef] [Green Version]
  40. Kim, J.Y. Antioxidants in Sepsis. Korean J. Crit. Care Med. 2010, 25, 57–60. [Google Scholar] [CrossRef]
  41. Fu, H.; Hu, Z.; Di, X.; Zhang, Q.; Zhou, R.; Du, H. Tenuigenin exhibits protective effects against LPS-induced acute kidney injury via inhibiting TLR4/NF-κB signaling pathway. Eur. J. Pharmacol. 2016, 791, 229–234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Arsenijevic, D.; Cajot, J.-F.; Dulloo, A.G.; Montani, J.-P. Uninephrectomy in rats on a fixed food intake results in adipose tissue lipolysis implicating spleen cytokines. Front. Physiol. 2015, 6, 195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Figure 1. The effects of xanthine oxidase inhibition on high-cholesterol diet-induced cholesterol accumulation, oxidative stress, and damage in the kidney. (A) Representative images of periodic acid Schiff (PAS) staining of kidney tissue. Scale bars, 100 μm. (BD) Levels of blood kidney injury factors (BUN and creatinine) and kidney/body weight in mice from different groups. (EG) Serum cholesterol levels in mice from different groups. (H) Representative images of Oil red O staining of kidney tissue (upper: cortex, lower: inner-medullar). Scale bars, 100 μm. (IK) Total cholesterol, free cholesterol, and cholesterol ester levels in the kidney. (LN) Xanthine oxidase activity, DCFDA, and H2O2 production in kidney tissue. Differences among the groups were analyzed by a one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. NC, # p < 0.05 vs. HC, § p < 0.05 vs. HC+UN. TP, topiroxostat; UN, uninephrectomy; NC, normal control; HC, high-cholesterol.
Figure 1. The effects of xanthine oxidase inhibition on high-cholesterol diet-induced cholesterol accumulation, oxidative stress, and damage in the kidney. (A) Representative images of periodic acid Schiff (PAS) staining of kidney tissue. Scale bars, 100 μm. (BD) Levels of blood kidney injury factors (BUN and creatinine) and kidney/body weight in mice from different groups. (EG) Serum cholesterol levels in mice from different groups. (H) Representative images of Oil red O staining of kidney tissue (upper: cortex, lower: inner-medullar). Scale bars, 100 μm. (IK) Total cholesterol, free cholesterol, and cholesterol ester levels in the kidney. (LN) Xanthine oxidase activity, DCFDA, and H2O2 production in kidney tissue. Differences among the groups were analyzed by a one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. NC, # p < 0.05 vs. HC, § p < 0.05 vs. HC+UN. TP, topiroxostat; UN, uninephrectomy; NC, normal control; HC, high-cholesterol.
Ijms 21 07444 g001
Figure 2. TP decreased cholesterol accumulation in the kidney through regulation of genes involved in cholesterol transport and synthesis. Real-time RT-PCR was performed to determine the expression levels of genes involved in cholesterol efflux (A,B), LDL receptor (C), modified LDL influx transport (D,E), cholesterol esterase (F), triglyceride synthesis (G), and cholesterol synthesis (H,I). (JL) Representative western blot for LXRα, ABCA1, HMGCR, and GAPDH. Relative protein expression was determined using densitometry. Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. NC, # p < 0.05 vs. HC, § p < 0.05 vs. HC+UN. LDL, low-density lipoprotein; TP, topiroxostat; UN, uninephrectomy; NC, normal control; HC, high-cholesterol.
Figure 2. TP decreased cholesterol accumulation in the kidney through regulation of genes involved in cholesterol transport and synthesis. Real-time RT-PCR was performed to determine the expression levels of genes involved in cholesterol efflux (A,B), LDL receptor (C), modified LDL influx transport (D,E), cholesterol esterase (F), triglyceride synthesis (G), and cholesterol synthesis (H,I). (JL) Representative western blot for LXRα, ABCA1, HMGCR, and GAPDH. Relative protein expression was determined using densitometry. Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. NC, # p < 0.05 vs. HC, § p < 0.05 vs. HC+UN. LDL, low-density lipoprotein; TP, topiroxostat; UN, uninephrectomy; NC, normal control; HC, high-cholesterol.
Ijms 21 07444 g002
Figure 3. Effects of xanthine oxidase inhibitor on the expression of genes related to cholesterol transport and synthesis and ROS in LDL-stimulated HK-2 cells. Real-time RT-PCR was performed to determine the expression levels of genes related to cholesterol efflux (A,B), the LDL receptor (C), triglyceride synthesis (D), and cholesterol synthesis (E,F). (G) After pretreatment with TP (5 or 10 μM) for 1 h, and stimulation with LDL (200 μg/mL) for 30 min, cellular ROS generation was measured based on the fluorescence intensity of DCF. (H,I) Measurement of H2O2 and DCFDA production. Quantitative PCR was performed to analyze the relative mRNA expression of NOX1 (J), NOX2 (K), and the NADPH oxidase subunits p22phox (L), p47phox (M). Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. NAC was used as a positive control. Data represent mean and SEM. * p < 0.05 vs. Control, § p < 0.05 vs. LDL. TP, topiroxostat; LDL, low-density lipoprotein; DCF, dichlorofluorescein.
Figure 3. Effects of xanthine oxidase inhibitor on the expression of genes related to cholesterol transport and synthesis and ROS in LDL-stimulated HK-2 cells. Real-time RT-PCR was performed to determine the expression levels of genes related to cholesterol efflux (A,B), the LDL receptor (C), triglyceride synthesis (D), and cholesterol synthesis (E,F). (G) After pretreatment with TP (5 or 10 μM) for 1 h, and stimulation with LDL (200 μg/mL) for 30 min, cellular ROS generation was measured based on the fluorescence intensity of DCF. (H,I) Measurement of H2O2 and DCFDA production. Quantitative PCR was performed to analyze the relative mRNA expression of NOX1 (J), NOX2 (K), and the NADPH oxidase subunits p22phox (L), p47phox (M). Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. NAC was used as a positive control. Data represent mean and SEM. * p < 0.05 vs. Control, § p < 0.05 vs. LDL. TP, topiroxostat; LDL, low-density lipoprotein; DCF, dichlorofluorescein.
Ijms 21 07444 g003
Figure 4. The effects of small interfering RNA against XDH (siXDH) on cholesterol metabolism and oxidative stress in LDL-stimulated HK-2 cells. After transfection with siXDH (20 μM) for 24 h, and stimulation with LDL (200 μg/mL) for 30 min, real-time RT-PCR was performed to determine expression levels of cholesterol efflux genes (A,B), LDL receptor (C), triglyceride synthesis (D), cholesterol synthesis (E,F), XDH (G), NOX1 (H), NOX2 (I), and the NADPH oxidase subunits p22phox (J) and p47phox (K). Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. control, § p < 0.05 vs. LDL. LDL, low-density lipoprotein.
Figure 4. The effects of small interfering RNA against XDH (siXDH) on cholesterol metabolism and oxidative stress in LDL-stimulated HK-2 cells. After transfection with siXDH (20 μM) for 24 h, and stimulation with LDL (200 μg/mL) for 30 min, real-time RT-PCR was performed to determine expression levels of cholesterol efflux genes (A,B), LDL receptor (C), triglyceride synthesis (D), cholesterol synthesis (E,F), XDH (G), NOX1 (H), NOX2 (I), and the NADPH oxidase subunits p22phox (J) and p47phox (K). Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. control, § p < 0.05 vs. LDL. LDL, low-density lipoprotein.
Ijms 21 07444 g004
Figure 5. Abnormal lipid metabolism and oxidative stress induced by high-cholesterol diet affect inflammation and fibrosis progression in kidney tissue. (A) Representative images of TNF-α and CD68 staining of kidney tissue. Scale bars, 100 μm. (BD) Real-time RT-PCR was performed to determine mRNA levels of Il-1β, Il-18, and Nlrp3. (E) Representative images of hematoxylin and eosin staining and trichrome staining of kidney tissue. Scale bars, 100 μm. (FI) Real-time RT-PCR was performed to determine mRNA levels of Acta2, Cdh1, ColI, and Fn1. (J,K) Representative western blot for α-SMA, fibronectin, and GAPDH. Relative protein expression was determined using densitometry. Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. NC, # p < 0.05 vs. HC, § p < 0.05 vs. HC+UN. LDL, low-density lipoprotein; TP, topiroxostat; UN, uninephrectomy; NC, normal control; HC, high-cholesterol.
Figure 5. Abnormal lipid metabolism and oxidative stress induced by high-cholesterol diet affect inflammation and fibrosis progression in kidney tissue. (A) Representative images of TNF-α and CD68 staining of kidney tissue. Scale bars, 100 μm. (BD) Real-time RT-PCR was performed to determine mRNA levels of Il-1β, Il-18, and Nlrp3. (E) Representative images of hematoxylin and eosin staining and trichrome staining of kidney tissue. Scale bars, 100 μm. (FI) Real-time RT-PCR was performed to determine mRNA levels of Acta2, Cdh1, ColI, and Fn1. (J,K) Representative western blot for α-SMA, fibronectin, and GAPDH. Relative protein expression was determined using densitometry. Differences among the groups were analyzed by one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. NC, # p < 0.05 vs. HC, § p < 0.05 vs. HC+UN. LDL, low-density lipoprotein; TP, topiroxostat; UN, uninephrectomy; NC, normal control; HC, high-cholesterol.
Ijms 21 07444 g005
Figure 6. Effects of xanthine oxidase inhibitor on progression of inflammation through the NF-κB pathway in LDL-treated HK-2 cells. (A,B) Representative western blot for NF-κB p50/p105 ratio, NF-κB p-p65/p65 ratio, and GAPDH in cells that were pretreated with TP (5 μM) for 1 h, and then stimulated with LDL (200 μg/mL) for 30 min. (CF) Representative western blot for NF-κB p50/p105 ratio, NF-κB p-p65/p65 ratio, IL-1b, NLRP3, and GAPDH in cells that were pretreated with NF-κB inhibitor (JSH23) for 1 h, and then stimulated with LDL (200 μg/mL) for 30 min. (GJ) Representative western blot for NF-κB p50/p105 ratio, NF-κB p-p65/p65 ratio, IL-1b, NLRP3, and GAPDH in cells that were pretreated with NF-κB inhibitor (BAY11-7028) for 2 h, and then stimulated with LDL (200 μg/mL) for 30 min. Relative protein expression was determined using densitometry. Differences among the groups were analyzed by a one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. Control, § p < 0.05 vs. LDL. LDL, low-density lipoprotein; TP, topiroxostat.
Figure 6. Effects of xanthine oxidase inhibitor on progression of inflammation through the NF-κB pathway in LDL-treated HK-2 cells. (A,B) Representative western blot for NF-κB p50/p105 ratio, NF-κB p-p65/p65 ratio, and GAPDH in cells that were pretreated with TP (5 μM) for 1 h, and then stimulated with LDL (200 μg/mL) for 30 min. (CF) Representative western blot for NF-κB p50/p105 ratio, NF-κB p-p65/p65 ratio, IL-1b, NLRP3, and GAPDH in cells that were pretreated with NF-κB inhibitor (JSH23) for 1 h, and then stimulated with LDL (200 μg/mL) for 30 min. (GJ) Representative western blot for NF-κB p50/p105 ratio, NF-κB p-p65/p65 ratio, IL-1b, NLRP3, and GAPDH in cells that were pretreated with NF-κB inhibitor (BAY11-7028) for 2 h, and then stimulated with LDL (200 μg/mL) for 30 min. Relative protein expression was determined using densitometry. Differences among the groups were analyzed by a one-way non-parametric ANOVA, followed by Tukey’s multiple comparison test. Data represent mean and SEM. * p < 0.05 vs. Control, § p < 0.05 vs. LDL. LDL, low-density lipoprotein; TP, topiroxostat.
Ijms 21 07444 g006
Table 1. Oligonucleotide primer sequences.
Table 1. Oligonucleotide primer sequences.
GeneForward Primer (5′–3′)Reverse Primer (5′–3′)
Mouse Msr1 CAC GGG ACG CTT CCA GAA TTGG ACT GAC GAA ATC AAG GAA TT
Mouse Scarb1 GGC CTG TTT GTT GGG ATG AACGT TCC ATT TGT CCA CCA GAT
Mouse Lcat AGC CTT GGC TGT CTG CAT GTCCCGAGAGAGATAAAACCATCAA
Mouse Srebf1 GGC TAT TCC GTG AAC ATC TCC TAATC CAA GGG CAT CTG AGA ACT C
Mouse Srebf2GGT CCT CCA TCA ACG ACA AAA TTAA TCA ATG GCC TTC CTC AGA AC
Mouse Nr1h3GAG TGT CGA CTT CGC AAA TGCCCT CTT CTT GCC GCT TCA GT
Mouse Abca1GGC AAT GAG TGT GCC AGA GTT ATAG TCA CAT GTG GCA CCG TTT T
Mouse LdlrCCAAATGGCATCACACTAGATCTTCCGATTGCCCCCATTG
Mouse HmgcrGGG CCC CAC ATT CAC TCT TGCC GAA GCA GCA CAT GAT CT
Mouse Il-1βTCG TGC TGT CGG ACC CAT ATGGTTCTCCTTGTACAAAGCTCATG
Mouse Nlrp3TCTCCCGCATCTCCATTTGTACGC GCG TTC CTG TCC TT
Mous Il-18GACAACTTTGGCCGACTTCACTCCTCGAACACAGGCTGTCTT
Mouse Acta2CTGACAGAGGCACCACTGCATCTCCAGAGTCCAGCA
Mouse CdhGCAGTTCTGCCAGAGAAACCTGGATCCAAGATGGTGATGA
Mouse Fn1CCA TTC TCC TTC TTC AAG TTT GCAGG AAT GGC TGT CAG GAT GGT
Mouse Col1ACA ACC GCT TTG CCA CTT CTCGT AAG TCA CGG GCA CGT T
Mouse GapdhTAA AGG GCA TCC TGG GCT ACA CTTTA CTC CTT GGA GGC CAT GTA GG
Human LDLRAGT TGG CTG CGT TAA TGT GAC ATCT CTA GCC ATG TTG CAG ACT TTG
Human SREBF1GCT CCT CCA TCA ATG ACA AAA TCTGC AGA AAG CGA ATG TAG TCG AT
Human SREBF2AGG CGG ACA ACC CAT AAT ATC ACTT GTG CAT CTT GGC GTC TGT
Human ABCA1GAC ATC GTG GCG TTT TTG GCGA GAT ATG GTC CGG ATT GC
Human HMGCRGGA CAG GAT GCA GCA CAG AAGCATGGTGCAGCTGATATATAAATCT
Human NR1H3CAC CTA CAT GCG TCG CAA GTCAG GCG GAT CTG TTC TTC TGA
Human NOX1TGCCTAGAAGGGCTCCAAACACATTCAGCCCTAACCAAACAAC
Human NOX2AGGGTCAAGAACAGGCTAAGGATTCTCCACCTCCAACCCTCTTT
Human p47phoxGGCAGGACCTGTCGGAGAAATCGCCCCTGCCTCAATAG
Human p22phoxACTTTGGTGCCTACTCCATTGTGTGTCCCCAGCGCTCCAT
Human XDHGAAGGCCATCTATGCATCGAAGAAGGCCATCTATGCATCGAA
Human GAPDHTTCACCACCATGGAGAAGGCTTGGTTCACACCCATGACGAAC
Table 2. List of antibodies used in immunohistochemistry and immunoblotting.
Table 2. List of antibodies used in immunohistochemistry and immunoblotting.
AntibodiesCat. No.Company
LXRαAb176323abcam
HMGCRAb174830abcam
ABCA1Ab18180abcam
α-SMAAb5694abcam
FibronectinAb2413abcam
IL-1β12242Cell signaling
NLRP313158Cell signaling
NF-kappaB p658242SCell signaling
NF-kappaBphos-p653036SCell signaling
NF-kappaBp105/p503035SCell signaling
GAPDH2118SCell signaling

Share and Cite

MDPI and ACS Style

Kim, Y.-J.; Oh, S.-H.; Ahn, J.-S.; Yook, J.-M.; Kim, C.-D.; Park, S.-H.; Cho, J.-H.; Kim, Y.-L. The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia. Int. J. Mol. Sci. 2020, 21, 7444. https://doi.org/10.3390/ijms21207444

AMA Style

Kim Y-J, Oh S-H, Ahn J-S, Yook J-M, Kim C-D, Park S-H, Cho J-H, Kim Y-L. The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia. International Journal of Molecular Sciences. 2020; 21(20):7444. https://doi.org/10.3390/ijms21207444

Chicago/Turabian Style

Kim, You-Jin, Se-Hyun Oh, Ji-Sun Ahn, Ju-Min Yook, Chan-Duck Kim, Sun-Hee Park, Jang-Hee Cho, and Yong-Lim Kim. 2020. "The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia" International Journal of Molecular Sciences 21, no. 20: 7444. https://doi.org/10.3390/ijms21207444

APA Style

Kim, Y. -J., Oh, S. -H., Ahn, J. -S., Yook, J. -M., Kim, C. -D., Park, S. -H., Cho, J. -H., & Kim, Y. -L. (2020). The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia. International Journal of Molecular Sciences, 21(20), 7444. https://doi.org/10.3390/ijms21207444

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop